clinical trial · NCT07154264
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Dizal (Jiangsu) Pharmaceutical Co., Ltd.·phase2·recruiting·n = 66
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDZD8586Venetoclax
brief summary
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
started
Sep 22, 2025
primary completion
Dec 1, 2029
completion
Jan 1, 2030
last updated
Dec 24, 2025
official title
A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol